Impact of Blood-Count-Derived Inflammatory Markers in Psoriatic Disease Progression
Life · 12.01.2024 · 14 (1) · 114
DOI: 10.3390/life14010114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 12.01.2024. Verfasst von Oana Mirela Tiucă und 5 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu M…. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Psoriasis is a chronic immune-mediated disease, linked to local and systemic inflammation and predisposing patients to a higher risk of associated comorbidities. Cytokine levels are not widely available for disease progression monitoring due to high costs. Validated low-cost and reliable markers are needed for assessing disease progression and outcome. This study aims to assess the reliability of blood-count-derived inflammatory markers as disease predictors and to identify prognostic factors for disease severity. Patients fulfilling the inclusion criteria were enrolled in this study. Patients were divided into three study groups according to disease severity measured by the Body Surface Area (BSA) score: mild, moderate, and severe psoriasis. White blood cell count (WBC), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), derived neutrophil-to-lymphocyte ratio (d-NLR), systemic immune index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI) positively were correlated with disease severity (p < 0.005). d-NLR, NLR, and SII are independent prognostic factors for mild and moderate psoriasis (p < 0.05). d-NLR is the only independent prognostic factor for all three study groups. Moderate psoriasis is defined by d-NLR values between 1.49 and 2.19. NLR, PLR, d-NLR, MLR, SII, SIRI, and AISI are useful indicators of systemic inflammation and disease severity in psoriasis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania.
- Dermatology Department, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania.
- Dermatology Clinic, Mures Clinical County Hospital, 540342 Targu Mures, Romania.
- Pathophysiology Department, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania.
- Endocrinology Department, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania.
- Endocrinology Department, Mures Clinical County Hospital, 540139 Targu Mures, Romania.
ORCID-Profile: Robert Aurelian Tiucă, Alin Codrut Nicolescu
Zitieren
APA
Tiucă, O. M., Morariu, S. H., Mariean, C. R., Tiucă, R. A., Nicolescu, A. C., & Cotoi, O. S. (2024). Impact of Blood-Count-Derived Inflammatory Markers in Psoriatic Disease Progression. Life, 14(1), 114. https://doi.org/10.3390/life14010114
Vancouver
Tiucă OM, Morariu SH, Mariean CR, Tiucă RA, Nicolescu AC, Cotoi OS. Impact of Blood-Count-Derived Inflammatory Markers in Psoriatic Disease Progression. Life. 2024;14(1):114. doi:10.3390/life14010114
BibTeX
@article{Tiuc2024,
author = {Tiucă, Oana Mirela and Morariu, Silviu Horia and Mariean, Claudia Raluca and Tiucă, Robert Aurelian and Nicolescu, Alin Codrut and Cotoi, Ovidiu Simion},
title = {Impact of Blood-Count-Derived Inflammatory Markers in Psoriatic Disease Progression},
journal = {Life},
year = {2024},
volume = {14},
number = {1},
pages = {114},
doi = {10.3390/life14010114}
}
EUVIMED